Kluwer Patent Blog

International Law Talk Podcast: EU Competition Law Developments in the Pharmaceutical Sector with Michael Clancy and David Hull

Lena Hornkohl (Deputy Editor) (University of Vienna, Austria) · Thursday, June 3rd, 2021

We are happy to announce the new International Law Talk Podcast episode on EU competition law developments in the pharmaceutical sector. And this one is twice as good! Not only are we discussing both competition and IP issues, but I also interviewed two leading experts in the field: Michael Clancy and David Hull from Van Bael & Bellis.

In the podcast, we touch upon new pharma developments regarding the Covid IP waivers, patent settlements, patent late life cycle strategies, biosimilars, excessive pricing, merger control and much more. Listen to the podcast!

In case you want to learn more on competition law and pharma, the new edition of the book by Van Bael & Bellis on Competition Law of the European Union has a great new section on the topic.

https://wolterskluwerblogs.com/competition/wp-content/uploads/sites/51/2021/06/KLI-11-trailer.mp4

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer

Leading change

🕩. Wolters Kluwer

This entry was posted on Thursday, June 3rd, 2021 at 2:25 pm and is filed under Competition, European Union, Pharma, Pharmaceutical patent

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.